Prevail Therapeutics to Present at Morgan Stanley 2019 Global Healthcare Conference NEW YORK, Sept. 04, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene...

Prevail Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights IND Active for Phase 1/2 Trial of PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations Successful $125.0 Million Initial Public Offering Completed to Support Program Advancement and...

Prevail Therapeutics to Present at 2019 Wedbush PacGrow Healthcare Conference NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients...

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Parkinson’s Disease Patients with a GBA1 Mutation NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients...